Replaces the term "the drug naloxone" with the term "opioid antagonist" in chapters regulating life insurance policies and group life insurance policies.
Impact
The enactment of HB 7719 is expected to have a notable impact on the state's insurance regulations, particularly in how life insurance companies assess applications from individuals with opioid antagonist prescriptions. By prohibiting discrimination based on these prescriptions, the bill aims to enhance coverage fairness and accessibility for individuals concerned about opioid-related issues. Furthermore, any denial of life insurance that violates the provisions outlined in this bill would be declared void, requiring insurers to reconsider applications retroactively. This change could lead to greater financial security for families who may be affected by opioid crises.
Summary
House Bill 7719 is an act aimed at protecting individuals who have prescriptions for naloxone, an important medication used to counteract the effects of opioid overdose, specifically within the realm of life insurance policies. The bill's primary objective is to replace the term 'naloxone' with 'opioid antagonist' in relevant chapters of the state's insurance laws, thereby ensuring that no life insurance company can deny coverage solely based on the applicant's possession of such a prescription. This is a significant protective measure for those at risk of opioid overdoses and potentially opens access to necessary life insurance for vulnerable populations.
Contention
While this bill has received support for its intention to prevent discrimination against individuals with opioid prescriptions, it may face contention surrounding its implementation and the real-world implications for insurance companies. Opponents might argue that mandating coverage without additional actuarial analysis could expose insurers to increased risk, thus impacting their financial stability and the integrity of the insurance market. Ultimately, the discussions surrounding the potential repercussions of HB 7719 will likely shape how effectively it can be integrated into the existing legal framework surrounding life and health insurance.
Replaces the term "the drug naloxone" with the term "opioid antagonist" in chapters regulating life insurance policies and group life insurance policies.
Health: pharmaceuticals; authority of certain physicians issuing standing orders; provide for. Amends secs. 9204 & 17744e of 1978 PA 368 (MCL 333.9204 & 333.17744e).
A bill for an act relating to controlled substances including the manufacture, delivery, or possession of a controlled substance including fentanyl; the manufacture of a controlled substance in the presence of a minor; conspiracy to manufacture for delivery or delivery or intent or conspiracy to deliver a controlled substance to a minor; receipt, provision, and administration of opioid antagonists, including by secondary distributors; providing for immunity; and providing penalties. (Formerly HSB 104.) Effective date: 07/01/2023.
Funds under management of the state investment board, opioid antagonist prescription, distribution, possession, or use, and the funding of the opioid treatment and prevention program; to provide an appropriation; to provide for a transfer; to provide for application; and to declare an emergency.